Health Technology
Sysmex Corp.
In the news
- Coronavirus-testing robot in Japan takes on key tasks, reducing lab strain Jun 4, 2020
- Rapid-fire coronavirus kits aim to fill Japan's testing gap Apr 2, 2020
- Robot injections? Makers look to bring automation to health care Apr 16, 2018
- Otsuka invests in startup making iPS-derived blood platelets Dec 25, 2017
- Tomorrow's game: Offshore production with robots Dec 7, 2017 See more articles on Sysmex Corp.
Business Summary
Sysmex Corp. engages in the healthcare business. It develops, manufactures, sells, exports, and imports diagnostic instruments, reagents. and software used in in-vitro diagnostics. It also provides clinical laboratory testing of blood, urine, and other specimens. Its products include instruments and reagents diagnostics for hemostasis, immunochemistry, clinical chemistry, urinalysis, and point-of-care (POC) testing. It operates through the following geographical segments: Japan, Americas, Europe, Middle East, and Africa (EMEA), China, and Asia Pacific. The company was founded by Taro Nakatani on February 20, 1968 and is headquartered in Kobe, Japan.
Financial Highlights
| Mar 2020 | JPY | USD |
| Revenue | 301,980M | 2,777.44M |
| Gross Profit | 159,807M | 1,469.81M |
| Operating income | 54,501M | 501.27M |
| Income before tax | 49,433M | 454.65M |
| Net income | 34,882M | 320.82M |
| EBITDA | 78,456M | 721.59M |
| Diluted EPS | 166.92 | 1.53 |
| Dividends Per Share | 72 | 0.66 |
| Total Assets | 389,291M | 3,606.04M |
| Total liabilities | 110,941M | 1,027.65M |
| Total equity | 277,684M | 2,572.21M |
| Operating cash flow | 53,182M | 489.13M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
| Revenue | 252,622M | 249,899M | 281,935M | 293,506M | 301,980M |
| Gross Profit | 150,690M | 141,777M | 158,949M | 161,607M | 159,807M |
| Operating income | 60,710M | 50,822M | 59,947M | 60,799M | 54,501M |
| Income before tax | 57,809M | 48,946M | 58,117M | 57,955M | 49,433M |
| Net income | 39,278M | 40,635M | 39,221M | 41,224M | 34,882M |
| EBITDA | 72,820M | 63,203M | 74,590M | 76,641M | 78,456M |
| Diluted EPS | 188.30 | 194.74 | 187.84 | 197.28 | 166.92 |
| Dividends Per Share | 52 | 58 | 66 | 70 | 72 |
| Total Assets | 263,917M | 279,817M | 321,979M | 346,775M | 389,291M |
| Total liabilities | 82,864M | 71,248M | 80,531M | 81,588M | 110,941M |
| Total equity | 182,801M | 209,407M | 240,750M | 264,449M | 277,684M |
| Operating cash flow | 41,794M | 32,832M | 52,240M | 44,743M | 53,182M |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
| Revenue | 2,103.70M | 2,307.73M | 2,543.79M | 2,646.70M | 2,777.44M |
| Gross Profit | 1,254.86M | 1,309.26M | 1,434.13M | 1,457.30M | 1,469.81M |
| Operating income | 505.56M | 469.32M | 540.87M | 548.25M | 501.27M |
| Income before tax | 481.40M | 452.00M | 524.36M | 522.61M | 454.65M |
| Net income | 327.08M | 375.25M | 353.87M | 371.74M | 320.82M |
| EBITDA | 606.40M | 583.65M | 672.99M | 691.11M | 721.59M |
| Diluted EPS | 1.56 | 1.79 | 1.69 | 1.77 | 1.53 |
| Dividends Per Share | 0.43 | 0.53 | 0.59 | 0.63 | 0.66 |
| Total Assets | 2,348.12M | 2,511.14M | 3,027.54M | 3,132.99M | 3,606.04M |
| Total liabilities | 737.25M | 639.39M | 757.22M | 737.11M | 1,027.65M |
| Total equity | 1,626.41M | 1,879.26M | 2,263.75M | 2,389.20M | 2,572.21M |
| Operating cash flow | 348.03M | 303.19M | 471.34M | 403.47M | 489.13M |
Valuation Measures
| Mar 2020 | |
| PER | 46.95 |
| ROA | 9.47% |
| ROE | 12.86% |
| Operating margin | 18.04% |
| Profit margin | 11.55% |
Key executives
- Chairman, Chief Executive Officer & President: Hisashi Ietsugu
- Director, CTO & COO-LS Business Unit: Kaoru Asano
- CFO, Director & Senior Managing Executive Officer: Yukio Nakajima
- Manager-Informatics: Yasuhiro Takachi
- Executive Officer: Keiji Fujimoto
Shareholders
- Baillie Gifford & Co. (5.9%)
- Kobe Yamabuki Foundation (5.7%)
- Nakatani Foundation (5.6%)
- Nakatani Kosan YK (4.9%)
- IETSUGU KAZUKO (2.9%)
- WADA TAEKO (2.9%)
- The Vanguard Group, Inc. (2.6%)
- IETSUGU FAMILY (2.2%)
- Nomura Asset Management Co., Ltd. (2.1%)
- NAKATANI TADAKO (1.9%)
Contact Details
- Website:http://www.sysmex.co.jp
- Address: 1-5-1 Wakinohama-Kaigandori, Chuo-Ku, Kobe, 651-0073, Japan
- Phone: +81.78.265.0500
Related Companies
- Oxford Gene Technology (Operations) Ltd.
- Sysmex Medical Electronics (Shanghai) Co., Ltd.
- Sysmex Wuxi Co. Ltd.
- Sysmex Inostics, Inc.
- Sysmex Turkey Diagnostik Sistemleri Ltd. STI
- Sysmex (Malaysia) Sdn.Bhd.
- Sysmex Vietnam Co. Ltd.
- Sysmex Taiwan Co. Ltd.
- Sysmex Suisse AG
- Sysmex Slovakia sro
- Sysmex Shanghai Ltd.
- Sysmex RUS LLC
- Sysmex Polska Sp zoo
- Sysmex Philippines, Inc.
- Sysmex Hungaria Kft.
- Sysmex Hong Kong Ltd.
- Sysmex Espana SL
- Sysmex do Brasil Industria e Comercio Ltda.
- Sysmex CZ sro
- Sysmex Canada, Inc.
- Sysmex Austria GmbH
- Sysmex Middle East FZ LLC
- Sysmex South Africa (Pty) Ltd.
- Sysmex Inostics GmbH
- Sysmex Korea Co., Ltd.
- Katakura Industries Co. Ltd. /Biological Research Center/
- Sysmex RA Co. Ltd.
- Sysmex Europe GmbH
- Sysmex Deutschland GmbH
- Sysmex TMC Co., Ltd.
Competitors
- bioMerieux SA
- Haemonetics Corporation
- Bio-Techne Corporation
- Guardant Health, Inc.
- Autobio Diagnostics Co., Ltd. Class A
- Epigenomics AG
- Genomictree, Inc.
- Biocept, Inc.
- Shanghai Runda Medical Technology Co., Ltd. Class A
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 3 Jul, 2020